Another implant manufacturer!

[Guest guest]

http://biz./prnews/050913/latu069.html?.v=29

MediCor Ltd. Announces Definitive Agreement to Acquire

Breast Implant Manufacturer Biosil Limited and

Supplier Nagor Limited

Tuesday September 13, 8:04 am ET

LAS VEGAS, Sept. 13 /PRNewswire-FirstCall/ -- Las

Vegas-based MediCor Ltd. (OTC Bulletin Board: MDCR -

News) announced today that it has signed a definitive

agreement to acquire British breast implant

manufacturer Biosil Limited and supplier Nagor Limited

for cash and stock.

Biosil and Nagor are privately owned companies located

in the United Kingdom, with sales of medical devices

worldwide. Biosil and MediCor's subsidiary, MediCor

Aesthetics, are currently party to a supply agreement

for saline-filled breast implants manufactured by

Biosil and imported into the United States, subject to

United States Food and Drug Administration approval to

market those products. The closing of the acquisition

is subject to customary conditions and is expected to

occur by the end of the year.

Nagor currently supplies the breast implant products

manufactured by Biosil in approximately 60 countries

throughout Europe, Asia, South America and Africa.

Biosil employs approximately 90 people in its two

ISO-certified manufacturing facilities, both of which

have additional production capacity, thus enhancing

MediCor's ability to meet increased product demand and

support new product introductions. With the

acquisition of Biosil and Nagor, MediCor believes it

now controls approximately 30% of the worldwide breast

implant market, excluding the United States.

Biosil develops and manufactures, and Nagor markets, a

full range of silicone implants for the aesthetic,

plastic and reconstructive surgery markets, including

silicone gel and saline-filled breast implants, with

both round and anatomical shapes and smooth or unique

micro-textured surfaces. Biosil also manufactures a

range of other silicone devices, including tissue

expanders, testicular implants, gluteal implants, calf

implants, facial implants and a range of scar

management products. Biosil has also developed

innovative products within the anesthesia and

colorectoral disciplines.

According to Theodore R. Maloney, MediCor's Chief

Executive Officer, " The acquisition of these

companies, combined with our existing Eurosilicone

breast implant product line, will further strengthen

the position of MediCor as the third leading

manufacturer and distributor of breast implants

worldwide, with Inamed Corporation and Mentor

Corporation in first and second position worldwide.

This acquisition continues the execution of our

long-term strategies of assembling the most

experienced management team and acquiring and

expanding businesses in the global aesthetic, plastic

and reconstructive and dermatology markets, continuing

the process started with our acquisition of

Eurosilicone in France in July 2004. We are proud to

unite in this effort with the Biosil and Nagor teams,

who, like the MediCor companies, are excited to

develop the world's highest quality and leading edge

product offerings and service for the growing

aesthetic, plastic and reconstructive surgery

markets. "

MediCor intends to retain the current Biosil and Nagor

employee base and expand operations, which are located

in Scotland, England and the Isle of Man.

Additionally, Alsop has agreed to continue in the

positions of President and Managing Director of Nagor

following the acquisition, helping maintain

consistency of quality, service and innovation.

Maloney also added that, " MediCor values the breadth

and strength of the two companies' existing third-

party distributors worldwide, and we look forward to

building upon those relationships. " Alsop added,

" This acquisition brings together a wealth of

experience within the plastic surgery field and will

allow the MediCor family of companies to uniquely

dovetail our core competencies, thereby realizing

significant efficiencies and allowing the MediCor

companies to leverage these competencies into market

leadership positions. We are excited to be part of the

continuing and ambitious growth of the MediCor group,

which will bring exciting new opportunities to our

customers, distributors and employees. "

MediCor Chairman, K. McGhan, further stated,

" Nagor and Biosil founders Gordon and and

I have had strong business associations for the past

40 years, dating back to the development of the first

silicone gel breast implant, at which time Gordon and

led the international marketing and sales of Dow

Corning's Medical Products Division. In the mid-1970s,

Gordon and accepted the opportunity to work at

McGhan Medical International located in Brussels,

Belgium. In 1979, they left McGhan Medical, then a

wholly owned subsidiary of 3-M Company, to start Nagor

and subsequently Biosil. We could not be more pleased

and honored to have this opportunity to be reunited

with Gordon and and benefit from the knowledge,

experience and integrity that both, along with

Alsop, have instilled in Nagor and Biosil. "

As part of the acquisition, MediCor has agreed to

grant certain rights to the selling shareholders to

have the MediCor stock to be issued to them in the

transaction registered with the Securities and

Exchange Commission. As a result, MediCor anticipates

that it will further amend and not seek effectiveness

of its current SB-2 registration statement on file

with the SEC until some time after the closing of the

acquisition of Biosil and Nagor.

MediCor was founded by Chairman of the Board K.

McGhan, the pioneer of the modern day breast implant

industry. The Company acquires, develops, manufactures

and markets products for medical specialties in

aesthetic, plastic and reconstructive surgery and

dermatology markets. Products include surgically

implantable prostheses for aesthetic, plastic and

reconstructive surgery and scar management products.

Its products are sold worldwide to hospitals, surgery

centers and physicians through various distributors

and direct sales personnel. MediCor's strategy is to

be the leading integrator of selected international

medical device markets, technologies and corporations.

To achieve this strategy, MediCor intends to build

upon and expand its business lines, primarily in the

aesthetic, plastic and reconstructive surgery and

dermatology markets. MediCor intends to accomplish

this growth through the expansion of existing product

lines and offerings and through the acquisition of

companies and other assets, including intellectual

property rights or distribution rights.

This release may contain forward-looking statements

within the meaning of the Private Securities

Litigation Reform Act of 1995. Such statements are

based upon the current beliefs and expectations of

MediCor's management and are subject to significant

risks and uncertainties. Actual results may differ

from those set forth in the forward-looking

statements.

The following factors, among others, could cause

actual results to differ from those set forth in the

forward-looking statements: the ability to obtain

requisite financing, the risk of instability in the

capital markets in the U.S. and internationally, the

ability to obtain governmental approvals of the

transactions; the ability to satisfy any agreed

closing conditions; the risk that the businesses will

not be integrated successfully; the risk that cost

savings from acquisition transactions may not be

realized or may take longer to realize than expected;

disruption from transactions making it more difficult

to maintain relationships with customers, employees or

suppliers; increased competition and its effect on

pricing, spending, third-party relationships and

revenues; the outcome of certain political and legal

proceedings; the risk of new and changing regulations

in the U.S. and internationally. Additional factors

that could cause MediCor's results to differ

materially from those described in the forward-looking

statements can be found in the Annual Report on Form

10-KSB for the year ended June 30, 2004, and

subsequent Quarterly Reports on Form 10-QSB of MediCor

filed with the Securities and Exchange Commission and

available at the Securities and Exchange Commission's

Internet site (http://www.sec.gov).

----------------------------

Source: MediCor Ltd.